Trial Profile
MM21 - A multicenter, single arm, study of daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ALLG MM21
- 13 Dec 2022 Results of secondary analysis of the MM21 trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Planned interim analysis of the multi-centre single arm study MM21 (ACTRN12618001490268). presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results assessing the effect of DRd on PBSC mobilisation and to determine the outcomes of G-CSF (G) + cyclo and G +/-plerixafor mobilisation for patients with prior DRd exposure and to compare PBSC yields to patients mobilised after Velcade, Cyclophosphamide, Dexamethasone (VCD) based induction therapy presented at the 63rd American Society of Hematology Annual Meeting and Exposition